Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2020-01-13 Regulatory Filings
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Fem kliniker är nu öppnade till den registreringsgrundande kliniska fas III-studien SPARKLE med ledande läkemedelskandidaten Mangoral
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that several clinics are now open for patient inclusion in the Phase III clinical trial SPARKLE for the drug Mangoral. It details the study's purpose, regulatory approvals (FDA, BfArM, Läkemedelsverket), and provides contact information for further inquiries. This type of announcement, detailing progress in clinical trials and regulatory milestones, is typically classified as a general regulatory announcement or news release, rather than a comprehensive financial report (like 10-K or IR) or a specific investor presentation (IP). Since it is a formal announcement of company progress that doesn't fit neatly into the other specific categories (like ER, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (4128 chars) is short enough that it is clearly an announcement of activity rather than the full report itself.
2020-01-13 Swedish
Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB
Board/Management Information Classification · 99% confidence The document is a press release dated December 18, 2019, announcing the appointment of the Nomination Committee in preparation for the Annual General Meeting (AGM) scheduled for May 6, 2020. While the content relates to the upcoming AGM, the document itself is an announcement about the committee formation, not the AGM materials (AGM-R) or the proxy solicitation materials (PSI). Since it is an announcement concerning the governance structure leading up to the AGM, it falls under general corporate governance information. However, given the specific focus on the Nomination Committee, which prepares proposals for director elections and remuneration, it is closely related to governance and board structure. The most fitting category among the provided options for an announcement detailing the composition of a committee responsible for nominating board members is Governance Information (CGR), as it details internal rules/structure preparation. It is not a DEF 14A (Remuneration Information) as it only sets up the committee, nor is it the AGM materials themselves (AGM-R). Given the context of preparing for the AGM regarding board composition, CGR is the best fit.
2019-12-18 English
Valberedning utsedd inför årsstämma 2020 i Ascelia Pharma AB
AGM Information Classification · 91% confidence The document is a press release dated December 18, 2019, announcing the composition of the Nomination Committee (Valberedning) for the upcoming Annual General Meeting (AGM) scheduled for May 6, 2020. This announcement concerns the process leading up to the AGM, specifically regarding the nomination of board members and related proposals. This falls under the scope of corporate governance related to shareholder meetings. While it is related to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (PSI). It is an announcement about the committee responsible for preparing proposals for the AGM, which is a key component of corporate governance leading up to the meeting. However, none of the provided codes perfectly match 'Nomination Committee Announcement'. Given the context of corporate governance and shareholder meeting preparation, it is closest to Governance Information (CGR) or potentially a general Regulatory Filing (RNS). Since it deals specifically with the composition and mandate of the body preparing proposals for the AGM (including board elections), it is strongly related to Governance (CGR). If a more specific code existed for 'Nomination Committee Announcement', that would be chosen. Between the available options, CGR (Governance Information) is the most appropriate fit as it relates to the structure and process governing board appointments.
2019-12-18 Swedish
Ascelia Pharma utser Julie Waras Brogren till Chief Commercial Officer
Board/Management Information Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the appointment of Julie Waras Brogren as Chief Commercial Officer (CCO), detailing her background and expected start date. This type of announcement concerns changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information' (Code: MANG) is the most appropriate fit for announcing a new C-level executive joining the management team.
2019-12-09 Swedish
Ascelia Pharma appoints Julie Waras Brogren as Chief Commercial Officer
Board/Management Information Classification · 99% confidence The document is explicitly titled 'PRESS RELEASE' and announces the appointment of a new executive, Julie Waras Brogren, as Chief Commercial Officer (CCO). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The document is short and serves as an immediate public disclosure, not a comprehensive report like a 10-K or IR.
2019-12-09 English
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019
AGM Information Classification · 100% confidence The document is explicitly titled 'Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019' and details the resolutions adopted during that meeting, such as the adoption of accounts, election of the board, determination of remuneration, and resolutions on share issues and incentive programs. This content directly corresponds to the purpose of an Annual General Meeting (AGM) information release. Therefore, the appropriate classification is AGM-R.
2019-11-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.